Suppr超能文献

头孢他啶/阿维巴坦对来自INFORM监测项目(2015 - 2017年)的全球多药耐药克雷伯菌属菌株的体外活性评估。

Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).

作者信息

Rossolini Gian Maria, Stone Gregory G

机构信息

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, 50134 Florence, Italy.

Pfizer Inc., 558 Eastern Point Road, Groton, CT 06340, USA.

出版信息

Int J Antimicrob Agents. 2020 Sep;56(3):106111. doi: 10.1016/j.ijantimicag.2020.106111. Epub 2020 Jul 25.

Abstract

Infections caused by Klebsiella spp. are difficult to treat when these pathogens exhibit multidrug resistance (resistance to ≥3 drug classes). This study determined rates of multidrug-resistant (MDR) Klebsiella spp. among clinical isolates collected globally (Africa/Middle East, Asia, Oceania, Europe and Latin America, but not the USA) as part of the INFORM surveillance programme (2015-2017). In vitro antimicrobial activities of ceftazidime/avibactam (CAZ/AVI) and comparator antimicrobials against these MDR isolates were determined using CLSI broth microdilution methodology. MICs were interpreted using EUCAST 2019 breakpoints. By species, 38.4% (4555/11 864) of Klebsiella pneumoniae isolates were MDR, followed by 28.3% (452/1598) of Klebsiella aerogenes. The majority (69.5%) of MDR K. pneumoniae isolates were extended-spectrum β-lactamase (ESBL)-positive and carbapenemase-negative compared with 1.3% of MDR K. aerogenes. Globally, >92% of MDR K. pneumoniae isolates were resistant to amoxicillin/clavulanic acid, aztreonam, cefepime, ceftazidime or ceftriaxone. CAZ/AVI, colistin and tigecycline MIC values were 1-2 mg/L against the global collection of MDR K. pneumoniae and MDR K. aerogenes. Approximately 5% (216/4555) of all MDR K. pneumoniae isolates and 1.1% (5/452) of all MDR K. aerogenes isolates were resistant to CAZ/AVI. Rates of resistance to CAZ/AVI and colistin were low for MDR, ESBL-positive, carbapenemase-negative K. pneumoniae (0.1% and 3.0%, respectively). Resistance to CAZ/AVI was highest among MDR, carbapenemase-positive, metallo-β-lactamase (MBL)-positive K. pneumoniae (98.0%), whereas colistin resistance was highest among MDR, carbapenemase-positive, MBL-negative isolates (30.2%). The results of this study suggest that CAZ/AVI, colistin and tigecycline are potential treatment options for nosocomial infections caused by MDR Klebsiella spp. isolates.

摘要

当肺炎克雷伯菌属病原体表现出多重耐药性(对≥3类药物耐药)时,由其引起的感染很难治疗。本研究确定了作为INFORM监测计划(2015 - 2017年)一部分在全球(非洲/中东、亚洲、大洋洲、欧洲和拉丁美洲,但不包括美国)收集的临床分离株中多重耐药(MDR)肺炎克雷伯菌属的比例。使用CLSI肉汤微量稀释法测定了头孢他啶/阿维巴坦(CAZ/AVI)和对照抗菌药物对这些MDR分离株的体外抗菌活性。MIC值根据EUCAST 2019标准进行解释。按菌种来看,肺炎克雷伯菌分离株中有38.4%(4555/11864)为MDR,其次产气克雷伯菌为28.3%(452/1598)。大多数(69.5%)MDR肺炎克雷伯菌分离株为超广谱β-内酰胺酶(ESBL)阳性且碳青霉烯酶阴性,而MDR产气克雷伯菌的这一比例为1.3%。在全球范围内,>92%的MDR肺炎克雷伯菌分离株对阿莫西林/克拉维酸、氨曲南、头孢吡肟、头孢他啶或头孢曲松耐药。CAZ/AVI、黏菌素和替加环素对全球收集的MDR肺炎克雷伯菌和MDR产气克雷伯菌的MIC值为1 - 2mg/L。所有MDR肺炎克雷伯菌分离株中约5%(216/4555)以及所有MDR产气克雷伯菌分离株中1.1%(5/452)对CAZ/AVI耐药。MDR、ESBL阳性、碳青霉烯酶阴性的肺炎克雷伯菌对CAZ/AVI和黏菌素的耐药率较低(分别为0.1%和3.0%)。MDR、碳青霉烯酶阳性、金属β-内酰胺酶(MBL)阳性的肺炎克雷伯菌对CAZ/AVI的耐药率最高(98.0%),而MDR、碳青霉烯酶阳性、MBL阴性分离株对黏菌素的耐药率最高(30.2%)。本研究结果表明,CAZ/AVI、黏菌素和替加环素是治疗由MDR肺炎克雷伯菌属分离株引起的医院感染的潜在选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验